CMEs
Credits will be requested.
2 Travel Awards for Hematologists - Apply now!
Novartis grants 2 travel awards to attend the ESH meeting: 5th How to Diagnose and Treat CML/MPN, taking place from 5. to 7. March 2027 in Prague, Czech Republic
What can you expect from the award?
Mentorship
Travel, accommodation and registration fees*
*while adhering to 33% co-payment rule as outlined in Swiss Ordinance VITH
---
You must fulfill at least 2 of the following criteria:
Have a Hematology or Medical Oncology FMH title
Be an experienced speaker involved in previous events
Have published research on CML or MPN
Have been an investigator on clinical trials on CML or MPN
Have treated a significant number of patients with CML or MPN
Have been involved in local/international guidelines
Are a board member of a medical society
Apply by November 13th
Send your CV (max. 2 pages including link to publications), motivation letter (max. 1 page) & letter of recommendation (max. 1 page) to gabriela.fosado_wyhooge@novartis.com. The steering committee will nominate the winners among the applications and select according to the criteria listed above.
The program is aimed at physicians caring for hematology patients, typically at senior/attending physician level but also open to early-career consultants. It particularly targets clinicians who are keen to deepen their expertise in CML and MPN and who value the opportunity to disseminate newly acquired knowledge and extend their professional network
Steering Committee
Prof. Dr. med. Gabriela Bärlocher
Klinik für Hämatologie und Onkologie, Hirslanden Zürich
Dr. med. Thomas Lehmann
HOCH, Kantonsspital St.Gallen
Prof. Dr. med. Sara Christina Meyer, PhD
Inselspital, Bern
Registration
Schedule
-
NETWORKING LUNCH
-
Opening
Prof. Dr. med. Sara Christina Meyer, PhD
-
Introduction to speaker 1 and topics
Prof. Dr. med. Gabriela Bärlocher
-
Speaker 1: How to diagnose and treat CML (topics may include):
Optimizing treatment sequencing and modality
Selecting the right first-line TKI
Genetic hierarchy of CML
Role of combination therapies
Role of dose modification
Challenging clinical scenarios in daily practice
Suboptimal molecular responses
Resistance mechanisms and mutations
Additional genomic aberrations
Treatment-free remission (TFR)
TFR in CML and optimization of eligibility
The future CML treatment landscape
Fine tuning of ATP-competitive TKIs
New allosteric drugs
PROTAC and other innovations
-
Podium discussion and Q&A guided by Prof. Bärlocher
Prof. Dr. med. Gabriela Bärlocher
-
BREAK
-
Introduction Speaker 2
Dr. med. Thomas Lehmann
-
Speaker 2: How to diagnose and treat MPN (topics may include):
Redefining treatment goals in MPN
Targeting driver mutations
Targets with cytoreduction
Usefulness of front-line targeted therapies
Evolving management of MF
Current MF treatment algorithm
Upcoming options in MF therapy
Expanding options across the MPN spectrum
New options for PV, ET
Progress in Systemic Mastocytosis SM and MPN-MDS overlap
Challenging MPN cases and long-term management
Young patients
Rare mutations
Managing skin cancer in MPN
Long-term complications and surveillance
-
Podium discussion and Q&A guided by Dr. Lehmann
Dr. med. Thomas Lehmann
-
Prof. Meyer: Conclusion, Outlook and Closing
Prof. Dr. med. Sara Christina Meyer, PhD
Abbreviations: ATP, adenosine triphosphate; CML, chronic myeloid leukemia; ET, essential thrombocythemia; MF, Myelofibrosis; MPN, myeloproliferative neoplasms; PROTAC, proteolysis targeting chimera; PV, polycythemia vera; SM, Systemic Mastocytosis; TFR, treatment-free remission; TKI, tyrosine kinase inhibitor.
Location
Swiss Institute for Translational and Entrepreneurial Medicine
Freiburgstrasse 3, 3010 Bern, Switzerland
3010 Bern
FA-11790067 – 09 2026